Welcome to our dedicated page for Xilio Therapeutics news (Ticker: XLO), a resource for investors and traders seeking the latest updates and insights on Xilio Therapeutics stock.
Xilio Therapeutics, Inc. develops masked immuno-oncology therapies for people living with cancer. Company news centers on its proprietary masking technology, which is designed to localize anti-tumor activity within the tumor microenvironment, and on pipeline updates for masked biologics and multi-specific I-O molecules.
Recurring developments include preclinical data for programs such as XTX601, a masked T cell engager targeting CLDN18.2, updates on XTX501, a bispecific PD-1 / masked IL-2 program, and disclosures involving masked T cell engager programs targeting PSMA and STEAP1. News also covers financial results, scientific conference presentations, inducement equity grants, board composition, and capital-structure actions.
Xilio Therapeutics (XLO) granted non-qualified stock options to purchase 19,865 shares of common stock to two new employees, effective September 1, 2026, under its 2022 Inducement Stock Incentive Plan.
The options have an exercise price of $8.88 per share, equal to the closing price on September 1, 2026, and a ten-year term. Vesting covers 25% of the shares on the first anniversary of employment, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service. The awards were approved as inducement grants under Nasdaq Listing Rule 5635(c)(4) and are governed by the plan and individual stock option agreements.
Xilio Therapeutics (Nasdaq:XLO) reported second quarter 2026 results and key pipeline updates. The company received FDA clearance of its IND for XTX501, a bispecific PD‑1 / masked IL‑2, enabling initiation of a first‑in‑human Phase 1/2 trial in metastatic NSCLC and select advanced solid tumors in the second half of 2026, with initial Phase 1 NSCLC data expected in the second half of 2027.
Xilio is advancing IND‑enabling studies for potential first‑in‑class masked T cell engager programs targeting CLDN18.2 and PSMA+STEAP1, with IND submissions planned in the second half of 2027, and continues a Phase 2 trial of masked IL‑12 efarindodekin alfa. For Q2 2026, collaboration and license revenue was $18.7 million versus $8.1 million a year ago, R&D expenses were $14.6 million, G&A expenses were $7.6 million, and net loss was $6.4 million versus $15.8 million. Cash and cash equivalents were $136.0 million as of June 30, 2026, and Xilio expects its cash runway to extend into the first quarter of 2028.
Xilio Therapeutics (Nasdaq:XLO) granted non-qualified stock options to three new employees effective July 1, 2026, under its 2022 Inducement Stock Incentive Plan.
The grants cover 107,060 shares at an exercise price of $9.22 per share, with a ten-year term and time-based vesting, as an inducement under Nasdaq Listing Rule 5635(c)(4).
Xilio Therapeutics (Nasdaq:XLO) appointed Ben Harshbarger as chief legal officer, adding over 20 years of biopharmaceutical legal and executive experience to its leadership team. He previously held senior roles at Astria Therapeutics, Novelion Therapeutics, Aegerion, Cubist, ViaCell and Biogen.
Xilio highlights its masked immuno-oncology pipeline, including XTX501 and multiple masked T-cell engagers.
Xilio Therapeutics (Nasdaq:XLO) reported first quarter 2026 results and pipeline updates. Collaboration and license revenue rose to $12.6 million, with net loss narrowing to $9.5 million. Cash and equivalents totaled $150.3 million, supporting operations into early 2028.
The company advanced XTX501 toward an IND in mid-2026 and Phase 1 in the second half of 2026, progressed masked T cell engager programs including XTX601 and a PSMA+STEAP1 candidate, and achieved a $6.0 million AbbVie milestone.
Xilio Therapeutics (Nasdaq: XLO) granted a non-qualified stock option to a newly hired employee effective May 1, 2026, under its 2022 Inducement Stock Incentive Plan.
The option covers 1,982 shares at an exercise price of $8.32 per share (closing price May 1, 2026), has a ten-year term, and vests 25% after one year then monthly over 36 months, subject to continued service and plan terms.
Xilio Therapeutics (Nasdaq: XLO) presented new preclinical data for XTX601, a masked T cell engager targeting CLDN18.2, at AACR (Apr 17–22, 2026). XTX601 showed protease‑dependent, tumor‑selective activation, dose‑dependent anti‑tumor activity in multiple murine xenograft models, and favorable tolerability in non‑human primates with no cytokine release syndrome or liver enzyme changes. Xilio plans IND‑enabling studies and an IND submission for the program in 2027. The poster presentation is scheduled Apr 20, 2026, Poster Section 10, Board 11.
Xilio Therapeutics (Nasdaq: XLO) appointed Cheryl R. Blanchard, Ph.D. to its board of directors, effective April 16, 2026, and announced Christina Rossi stepped down effective April 15, 2026. Dr. Blanchard brings over 30 years of leadership across biologics, devices and commercial strategy, including current service as executive chair of Anika.
The company highlighted Dr. Blanchard's experience advancing programs through U.S. clinical and regulatory pathways and her operational and commercial leadership as relevant to Xilio's masked immuno-oncology pipeline.
Xilio Therapeutics (Nasdaq: XLO) granted inducement stock options effective April 1, 2026, to two new employees totaling 3,257 shares under its 2022 Inducement Stock Incentive Plan. The options carry an exercise price of $8.48 per share and a 10-year term.
Vesting: 25% on the first anniversary of employment, then the remaining 75% in 36 equal monthly installments, subject to continued service and plan/option agreement terms.
Xilio Therapeutics (Nasdaq: XLO) reported pipeline progress and Q4/full-year 2025 results. Key milestones include a planned XTX501 IND submission mid-2026, Phase 1 start H2 2026, candidate nomination for a multi-specific masked T cell engager in Q2 2026, and AACR data for a CLDN18.2 program in April 2026. Cash and cash equivalents were $137.5M at year-end, with an expected runway through end of 2027.